Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The research aimed to develop a validated model for predicting the risk of linezolid-induced thrombocytopenia (LIT). An XGBoost model and SelectFromModel method were used to screen the important factors. Based on the selected features, five models-Logistic Regression, XGBoost, Random Forest, Naive Bayes, and Support Vector Machine-were established. Finally, the model results were interpreted using SHAP. In this retrospective study, 187 patients were enrolled, and the incidence of LIT was 35.8%. An XGBoost model was established with good performance, in which the AUCs of the training set and validation set were all 0.9. The duration of linezolid treatment, ICU admission time, low baseline platelet level, shock, and concomitant use of piperacillin-tazobactam were significant risk factors for LIT. A moderately raised level of platelet-large cell ratio, total bilirubin, and weight may help reduce the incidence of LIT.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.70054DOI Listing

Publication Analysis

Top Keywords

linezolid-induced thrombocytopenia
8
xgboost model
8
incidence lit
8
model
5
development risk
4
risk prediction
4
prediction model
4
model linezolid-induced
4
thrombocytopenia based
4
based machine
4

Similar Publications

Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.

Antimicrob Agents Chemother

September 2025

Department of Infectious Diseases, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.

Despite the widespread pediatric use of linezolid, data on its hematologic toxicity-particularly among children exposed to anticancer chemotherapy-remain limited and inconsistent. This study aimed to evaluate linezolid-induced hematotoxicity through pharmacokinetic analysis, with an emphasis on chemotherapy-exposed pediatric patients. This dual-center prospective study assessed linezolid pharmacokinetics and clinical profiles in chemotherapy-stratified pediatric cohorts, examining associations with hematologic toxicity.

View Article and Find Full Text PDF

The research aimed to develop a validated model for predicting the risk of linezolid-induced thrombocytopenia (LIT). An XGBoost model and SelectFromModel method were used to screen the important factors. Based on the selected features, five models-Logistic Regression, XGBoost, Random Forest, Naive Bayes, and Support Vector Machine-were established.

View Article and Find Full Text PDF

Using Machine Learning to Predict Linezolid-Associated Thrombocytopenia.

Infect Drug Resist

May 2025

Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China.

Objective: Using artificial intelligence and machine learning to predict linezolid-induced thrombocytopenia helps identify related risk factors in patients.

Methods: Between January 2020 and December 2023, 284 patients receiving linezolid from Beijing Chaoyang Hospital were enrolled. The data underwent filtering to ensure completeness and quality.

View Article and Find Full Text PDF

Linezolid Related Adverse Effects in Different Populations: A Practical Review.

Curr Drug Saf

March 2025

Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Linezolid, an oxazolidinone antibiotic, is used to treat gram-positive infections. However, it may also lead to serious adverse effects, including bone marrow suppression, optic neuropathy, peripheral neuropathy, hyponatremia, and lactic acidosis. This review evaluates the existing evidence concerning the adverse effects of linezolid in patients undergoing treatment with this medication, both in the short and long term.

View Article and Find Full Text PDF

Development and validation of a nomogram to predict linezolid-induced thrombocytopenia in hospitalized adults.

BMC Pharmacol Toxicol

February 2025

Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Department of Pharmacy, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 20 Jinyu Avenue, Liangjiang New District

Background: Linezolid (LZD) is used to treat infectious diseases caused by Gram-positive bacteria, but thrombocytopenia is one of the main adverse reactions to LZD administration. Early prediction of linezolid-induced thrombocytopenia (LI-TP) is of great importance to improve the clinical outcomes and prognoses. The aim of this study was to develop and validate a prediction model for LI-TP.

View Article and Find Full Text PDF